HIMS partners with Novo Nordisk and withdraws patent lawsuit, what potential growth does this collaboration offer HIMS?

**Bottom-line 🎯:** The Novo Nordisk deal removes Hims & Hers’ biggest legal overhang and opens a direct telehealth channel to blockbuster GLP-1 drugs, but the growth story now hinges on volume conversion, margin discipline, and cross-selling into Hims’ broader health platform. 📈✨ --- ### Why the partnership matters 🤝💊 1. **Legal clarity = immediate sentiment boost.** • Hims shares jumped ~40 % on the news as the patent-infringement lawsuit was dropped, instantly lifting a multi-year cloud . • Analysts at Needham and Citi quickly raised price targets to $30 and $24, respectively, citing “reduced uncertainty” as a core thesis . • Barclays likewise called the deal a net positive because it avoids a costly multi-year trial . 🎉 2. **New revenue engine via branded GLP-1s.** • Hims will offer FDA-approved Ozempic® (0.5 mg, 1 mg, 2 mg) and Wegovy® (pills and injections) on its platform later this month . • Novo’s general counsel had previously branded Hims’ prior compounding as “egregious,” underscoring how this partnership legitimizes the channel . • Management had already guided to a $100 m run-rate in weight-loss revenue in <7 months, even before branded GLP-1s ; the new deal could super-charge that trajectory. 🚀 3. **Scale & stickiness potential.** • Hims serves >2.5 m subscribers, giving Novo a vast digital footprint to drive adoption of its high-margin obesity franchise . • The telehealth model lets Hims capture recurring revenue and data on patient outcomes, supporting upsell/cross-sell into nutrition, fitness, and mental-health services tied to weight-loss journeys . 🔄 --- ### Key growth levers to watch 🔍 | Growth Driver | Why It Matters | Data Point / Source | |---------------|---------------|---------------------| | Prescription volume conversion | Moving patients from compounded to branded drugs will dictate near-term revenue | Novo’s core GLP-1 franchise is “volume-focused” as pricing pressure builds | | Margin profile | Branded drugs sell at fixed prices, likely thinner than compounding margins | Barclays warns of “far lower margins” for Hims on branded GLP-1s | | Cross-sell rate | Ability to bundle weight-loss with other verticals (sexual health, lab testing, etc.) | Weight-loss is one pillar of a mix that also includes sexual health and lab testing | | Regulatory tailwinds | FDA crackdown on compounding pushes patients toward legitimate channels | FDA Commissioner supports Hims’ shift to approved products | --- ### Risks that could cap upside ⚠️ • **Margin squeeze:** Selling at Novo’s self-pay prices (~$149–$299/month) may compress Hims’ gross margin from the 60.86 % reported pre-deal to something closer to the 5.5 % cited post-transition . • **Execution risk:** Hims must prove it can convert telehealth traffic into sustained GLP-1 prescriptions without relying on cheaper compounding. • **Regulatory overhang isn’t gone:** Novo reserves the right to refile suit, and FDA guidance on compounding remains fluid . --- ### Investment takeaway 💡 The collaboration offers Hims a credible, legal pathway to ride the GLP-1 boom while de-risking a major lawsuit. Growth will be strongest if Hims can convert its large subscriber base into consistent branded drug volumes and monetize ancillary services. Investors should track quarterly weight-loss segment margins and cross-sell metrics to gauge execution quality. 📊 --- **Curious next step 🤔:** If Hims can maintain even half of its current 60 % gross margin while scaling GLP-1 scripts, how might that reshape your valuation model for the stock’s 2026 earnings? 🧐